

Generic IV Chemotherapy — Billing Cheat Sheet

18-drug rollup · Anchored on cyclophosphamide J9070 · CHOP / AC / ABVD / FOLFOX / 7+3 / BEAM · Q2 2026 ASP · Reviewed May 22, 2026

CareCost Estimate
carecostestimate.com/drugs/generic-iv-chemotherapy

#1 DENIAL: JW / JZ on MDV line. Per CMS CR 12056, multi-dose vials are EXCLUDED from JW / JZ. Common MDV on this rollup: **mesna 100 mg/mL MDV, 5-FU 50 mg/mL MDV** (most common 5-FU acquisition), **bleomycin 15U MDV**, some methotrexate 25 mg/mL MDV. SDV: JZ when fully used, JW + waste line if discarded. **Verify dispensed NDC presentation before locking the modifier.**

#2 DENIAL: 96416 vs 96417 confusion.
96416 = portable / implantable pump initiation (CIVI 5-FU 46-hr in FOLFOX / FOLFIRI / FOLFIRINOX). Reported **ONCE**.
96417 = sequential additional DIFFERENT drug, up to 1 hr. NOT the pump code. **Top miscode pattern.**

PER-DRUG HCPCS + REGIMEN + ADMIN + ASP

DRUG	HCPCS	UNIT	MOST-CITED REGIMEN	ADMIN CPT	SDV/MDV	ASP+6% Q2 2026
Cyclophosphamide (Cytoxan)	J9070	per 100 mg	AC / EC (breast); CHOP / R-CHOP (NHL); BEAM	96413 + 96415	SDV	No CMS entry — acq+handling
Ifosfamide (Ifex)	J9208	per 1 g	VIP (germ-cell); ICE; MAID (sarcoma)	96413 + 96415	SDV	\$24.682
Mesna (Mesnex)	J9209	per 200 mg	Uroprotectant: ifosfamide / HD-cyclo	96409 or 96413	MDV	\$1.334
Dacarbazine (DTIC)	J9130	per 100 mg	ABVD (Hodgkin); melanoma historical	96413	SDV	\$3.852
Daunorubicin	J9151	per 10 mg	7+3 AML induction	96409 / 96413	SDV	No entry
Idarubicin (Idamycin PFS)	J9211	per 5 mg	7+3 AML (alternative)	96409	SDV	\$39.756
Epirubicin (Ellence)	J9178	per 2 mg	EC / FEC (breast)	96409	SDV	\$1.767
Mitoxantrone	J9293	per 5 mg	AML reinduction	96413	SDV	\$38.614
5-Fluorouracil	J9190	per 500 mg	FOLFOX / FOLFIRI / FOLFIRINOX (CIVI 46-hr)	96409 bolus + 96416 pump	MDV MOSTLY	\$2.056
Methotrexate IV low	J9250	per 5 mg	Low-dose IV; verify J-code per MAC	96409 / 96413	SDV/MDV mix	No entry — use J9260
Methotrexate IV high (HD-MTX)	J9260	per 50 mg	CNS lymphoma; osteosarcoma; ALL	96413 + 96415 mult	SDV (PF only)	\$2.677
Cytarabine (Ara-C)	J9100	per 100 mg	7+3 SD CIVI; HiDAC consolidation	96413 + 96415	SDV	\$0.799
Leucovorin calcium	J0640	per 50 mg	FOLFOX / FOLFIRI; HD-MTX rescue	96409 / 96413	SDV	\$3.591
Vinblastine	J9360	per 1 mg	ABVD (Hodgkin)	96409	SDV	\$5.152
Vincristine	J9370	per 1 mg	CHOP / R-CHOP; hyper-CVAD; ALL	96409 / 96413 minibag	SDV	\$8.113
Goserelin (Zoladex)	J9202	per 3.6 mg	Prostate ADT; breast hormone	96402 (SC hormonal)	Single-use implant	\$777.502 (Q1 fallback)
Mitomycin	J9280	per 5 mg	Nigro (anal SCC); intravesical bladder	96409 or 51720 intravesical	SDV (mostly)	\$28.459
Bleomycin sulfate	J9040	per 15 units	ABVD (Hodgkin); BEP (testicular)	96409 / 96413	MDV	\$16.598

NCCN compliance is the unifying PA gate. Major payers (UHC / Aetna / BCBS / Cigna / Humana) auto-approve NCCN **Category 1 / 2A** regimens with regimen citation. Category 2B and off-label require biomarker / molecular / case rationale. Medicare FFS = no upfront PA (post-pay audit; off-label needs NCCN / AHFS-DI / Micromedex / DRUGDEX compendia support).

Patient assistance = FOUNDATIONS ONLY (no manufacturer copay cards for commodity generics):
CancerCare, PAN Foundation, HealthWell, LLS (blood cancers), BMS Foundation, Good Days, PAF Co-Pay Relief. Indication-driven (cancer ICD-10), not drug-driven. Funds open / close by diagnosis.

REGIMEN → DRUGS ON THIS ROLLUP (CROSS-LINK MAP)

CHOP / R-CHOP (NHL) — cyclophosphamide + vincristine + (doxorubicin*)

AC / AC-T (breast) — cyclophosphamide + (doxorubicin*)

EC (breast) — epirubicin + cyclophosphamide

ABVD (Hodgkin) — bleomycin + vinblastine + dacarbazine + (doxorubicin*)

BEACOPP — bleomycin + cyclophosphamide + vincristine + dacarbazine + (etoposide* + doxorubicin* + procarbazine + prednisone)

7+3 AML induction — cytarabine + daunorubicin OR idarubicin

HiDAC consolidation — cytarabine high-dose leucovorin + (oxaliplatin* / irinotecan*)

R-ICE / DHAP salvage — ifosfamide + mesna; cytarabine (DHAP)

BEP (testicular) — bleomycin + (etoposide* + cisplatin*)

VAC / VIE (sarcoma) — vincristine + cyclophosphamide + ifosfamide

Nigro (anal SCC) — mitomycin + 5-FU + radiation

HD-MTX (CNS / osteosarcoma) — methotrexate (J9260) + leucovorin rescue

Intravesical bladder — mitomycin (CPT 51720)

Prostate ADT / breast HD — goserelin (CPT 96402)

* = dedicated CareCost page (not on this rollup)

FOLFOX DAY-1 CMS-1500 EXAMPLE (THE MOST-BILLED CLAIM SHAPE)

LINE	CPT/HCPCS	MODIFIER	NOTES
1	96409	—	5-FU bolus IV push (initial substance, push)
2	96411	—	Leucovorin push (additional substance, push)
3	96413	—	Oxaliplatin 2-hr infusion (initial infusion drug)
4	96415	—	Each additional hour of oxaliplatin infusion
5	96416	—	CIVI 5-FU 46-hr pump initiation (ONCE per encounter)
6	J9190	No JW/JZ if MDV	5-FU total mg / 500 = units. Verify NDC.
7	J0640	JZ (SDV)	Leucovorin per 50 mg units
8	J9263	JZ	Oxaliplatin (see dedicated page)

TOP DENIAL FIXES (COMPRESSED)

PATTERN	FIX
JW / JZ on MDV line	Remove modifier; resubmit. Build NDC-to-modifier map at order entry.

PATTERN	FIX
96417 instead of 96416 on CIVI 5-FU	Correct CPT to 96416; pump-flag at order entry routes to 96416 auto.
Wrong methotrexate J-code (J9250 vs J9260)	Match J-code to dispensed NDC unit basis; align with MAC preferred code.
J0640 vs J0641 (leucovorin vs levoleucovorin)	Verify dispensed NDC; J0640 racemic, J0641 levo half-dose. Different products.
Missing mesna on ifosfamide claim	Add J9209 line; ifosfamide orderset should auto-generate mesna line.
NCCN-non-compliant denied	Append compendia citation + biomarker / molecular / case rationale; peer-to-peer if needed.
Missing Z51.11	Add Z51.11 (encounter for antineoplastic chemo) to every chemo admin line dx list.
POS 22/49 for inpatient AML 7+3	Withdraw J-code line; inpatient chemo = DRG-bundled, not separately billable on Part B.

Verify per claim. Full reference: carecostestimate.com/drugs/generic-iv-chemotherapy - Pending SME review. © 2026 CareCost Estimate. Reviewed May 22, 2026.